The primary endpoint of 12-month Event Free Survival (EFS) for OST-HER2- treated patients (35%) was statistically significant (p= 0.0194) when compared with peer-reviewed comparable historical control ...
Great. Thanks, everyone, so much for being here to close out day 3 of Communacopia. My name is Adam Hotchkiss, and I cover the emerging software space here at Goldman Sachs. We're really privileged to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results